Benign prostatic hyperplasia. Part 2--management

BMJ. 2008 Jan 26;336(7637):206-10. doi: 10.1136/bmj.39433.670718.AD.
No abstract available

Publication types

  • Review

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use
  • Antimutagenic Agents / therapeutic use
  • Cholestenone 5 alpha-Reductase / antagonists & inhibitors
  • Combined Modality Therapy
  • Humans
  • Male
  • Medical Laboratory Science
  • Phytotherapy / methods
  • Prostatic Hyperplasia / therapy*

Substances

  • Adrenergic alpha-Antagonists
  • Antimutagenic Agents
  • Cholestenone 5 alpha-Reductase